#RALLISINDIA Concall Highlights Q3FY22 🌱

Like & retweet for better reach !

Operational Highlights :

1. Q3 was challenging quarter due to unseasonal rains, pest infestation in chilli farms and change in regulatory framework
2. Revenue turned weak at 628 Cr (728 Cr in Q2FY22) due to challenges in demand and change in government regulations

3.EBITDA margins contracted to 11% (12% in previous quarter) due to high raw materials, freight and power expense
4. Export revenue grew by 19% whereas domestic revenue grew by only 9%

5. The growth was driven by value more than volumes as company mentioned about price hikes in previous quarter
Challenges in industry

1. The monsoon season this year has not favoured agri input companies as excessive rainfall continued into Q3 in the southern states
2. 50% increase in input costs due to tight supplies from China in Oct-Nov’21
3. Supply chain challenges continued into Q3 with availability being a challenge for certain intermediates as well as steep inflation in prices

4.The company faced logistic challenges and high international freight rates
5.Headwinds in the industry due to change in government regulations in certain states.

6. Reduced addressable market for cotton because of illegal cultivation
Business Strategy

1. Rabi sowing were up by 1% due to high water levels in reservoirs, this explains higher demand in rabi products portfolio
2. Working on environmental sustainable product and water soluble fertilisers
3. Looking for opportunities in crop nutrition segment
4. Company increased expenses on digital marketing initiatives.
5. Portfolio augmentation will help capture the demand in northern regions of UP, Andhra Pradesh and Rajasthan.
Acetamiprid, and Hexaconazole continues to stay strong
6.Focus on improving formulations share
7. Calibrated prices for products to pass on the incremental costs

Crop care segment review

1. 13.3% (YoY) growth in crop care segment
2. Focusing on increasing formulations in the international business
3. Metribuzin product showing signs of revival
4. International demand looks promising ,growth driven by good commodity prices

Seed segment review

1. Revenue were down 31% YoY
2. State action on ban of hybrid paddy seeds in southern states affected the demand
3. Bihar - change in regulatory environment, the new mandate
explains that the new products are to be sold only after approval by national authorities. Either state approvals or national approvals were accepted earlier.
New Product launch

1. 2 new crop nutrition products in Q3 - one biological nematicide and one nutrition product from agro waste
2. Launched 6 crop protection and 4 crop nutrition products in 9M.
3. Crop protection - 2 products launched in 9-3 and 9-4 each,
and two co-marketing products launched
4.Also launched Potash - rich organic manure product and new Maize hybrid in the hybrid seeds segment
5. Product in agro intermediate to be commercialised from the new MPP plant
Contract manufacturing

1. Revenue from CRAMS were largely impacted by lower offtake of PEKK due to subdued growth in the aviation sector.
2. Finalising 2 small contracts in the segment

Capex
1. MPP at Dahej is expected to be completed by H1FY23.
2. Pilot Plant at Dahej is already commissioned
3. Formulation facility Phase 1 commissioned, commercial production started
4.Two AI plants capacity enhanced and commercial production started at Ankleshwar(herbicide and insecticides)
Capex FY22E - ₹250cr, similar capex for subsequent financial years for new product

Debottlenecking largely completed

Overall outlook for demand seems strong with small headwinds from the regulatory authorities. Commercialization of existing capex will drive the future revenues

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Value Educator

Value Educator Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ValueEducator

Feb 26
Why 🎵 music labels is unique business model ?
@NeilBahal

Watch the video !
Link :

1. High Entry Barriers
It's not easy to create catalogue of 1 Lk songs in short time. Each movie will have 4-5 songs and in a year about 100 movies might be released, Image
so about 500 songs will be produced in a year. To create catalogue of 25000 songs it will need 50 years. Industry will keep consolidating, as bigger players will acquire the smaller music labels.
2. Get the acquisition costs recovered in 3-5 years and keep the content with you for lifetime without any incremental costs.
Keyword : Without incremental costs Image
Read 8 tweets
Feb 19
#Rossaribiotech Q3 2022 Concall Highlights

Like & retweet for better reach !

Operational Highlights

1. Revenues for the quarter stood at ₹428.4Cr, up 104% from same period previous year
2. EBITDA stood at ₹46.7 Cr translating to EBITDA margins of 10.9%

3. PAT stood at ₹22.5 Cr with PAT margins of 5.3%

4. Undertaking price hikes wherever possible to offset these raw material pressures.
5. This is the first full quarter of consolidation of recent acquisitions of Unitop and Tristar in Rossari’s performance. Both these companies delivered growth during the period, which assisted overall performance.
Read 14 tweets
Feb 19
#JBChemicals & Pharmaceuticals Q3 FY22 concall highlights 💊💊

Like & Retweet for better reach !

1. They were the fastest growing company among the Top 30 companies in the domestic formulations market as per IQVIA. JB grew at 27% vs market growth of 18%.
2. Revenues for the quarter stood at ₹601 Cr (10% growth YoY).

3. EBITDA excluding ESOP cost stood at ₹153 Cr (10.5% decline YoY). Gross margins for the quarter stood at 66% although there was significant cost inflation.
4. Cost pressure persists on raw material and packing material, which is expected to continue in the medium-term.

5. During Q3 FY22, Domestic Formulations business launched 12 new products including Molnupiravir, Cilacar TM, Azovas-T and Pirfenidone.
Read 12 tweets
Feb 19
#SequentScientific Q3 FY22 concall highlights 🐩🐕‍🦺

Like & Retweet for better reach !

Watch the video to understand the business details :


1. Revenues for the quarter stood at ₹358 Cr (4.8% growth YoY).
2. Growth was mainly driven by the Formulations business which grew at 18.5% YoY on a constant currency basis whereas the API business declined by 20% YoY driven by logistic challenges and subdued demand for Albendazole.
3. Growth in the API portfolio excluding Albendazole has been strong in the first 9 months. Albendazole demand still remains subdued but there is a strong recovery in demand QoQ.
Read 17 tweets
Feb 16
#Kiriindustries Q3 2022 Concall Highlights

Like & Retweet for better reach !

Operational Highlights

1. The revenues for Q3FY22 stood at ₹429.4Cr from ₹310.3 Cr in same period previous year accounting to growth of 38.4% YoY
2. EBITDA for the quarter stood at ₹48.5Cr translating to EBITDA margins of 11.29%

3. The contributors to Consolidated Net Profit after tax of ₹106.02Crore in Q3-FY22 include share of profit of DyStar (associate company of Kiri) to the tune of ₹81.49 Crore, and
₹13.44Crore from Lonsen Kiri Chemical Industries Limited

3. Consolidated Gross Margin has strengthened to 33%, a Q-o-Q increase of 3% which is further expected to improve in coming quarters
Read 12 tweets
Feb 15
#Nazaratechnologies Q3 2022 Concall Highlights 🎱🎲

Financial Update

1. For Q3FY22 revenue was ₹185.8 Cr vs ₹130.4 Cr in Q3FY21 a growth of 42% on YoY basis.

2. Q3 EBITDA was at ₹30.2 Cr as compared to ₹27.3 Cr in the same quarter of the previous year.
3. For 9M FY22 revenue was ₹446.6 Cr vs ₹330.8 Cr in 9MFY21 a growth of 35% on YoY basis.

4. 9MFY22 EBITDA surged by 141% to ₹79.7 Cr as compared to ₹33.1 Cr in 9MFY21.
5. Esports segment recorded revenue of ₹109.3 Cr in Q3FY22 vs ₹57.8 Cr last year in the same quarter, a growth of 89% YoY basis.
Their Gamified early learning segment recorded revenue of ₹47.2Cr.

6. Freemium segment had revenue of ₹5.7 Cr
Read 16 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(